Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human intestinal microbiota
- Development stage
- Unknown
- Lead developer
- Emory University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Human intestinal microbiota is a lyophilized, live biotherapeutic product being developed by Emory University for the treatment of multidrug-resistant organism (MDRO) colonization. [3, 6] The active ingredient consists of whole communities of beneficial bacteria derived from the fecal microbiota of healthy, screened donors. [3] The therapy's mechanism of action is to restore intestinal microbiome diversity, thereby providing colonization resistance against pathogenic bacteria. It is being evaluated in the FAIR trial, a Phase 2 study, for its ability to decolonize patients with MDROs such as CRE, VRE, and ESBL-producing organisms. The treatment is administered as a reconstituted suspension via gastrostomy tube or enema. [3]
- Other names
- fecal microbiota transplantmicrobiome therapeuticFMTMT
Beyond the preview
Go deeper on human intestinal microbiota.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human intestinal microbiota.